• About us
• Contact

Advertisement

Organisation › Details

Bico (Group)

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health. The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,850 publications. BICO is listed on Nasdaq Stockholm under BICO. *

 

	Start	2021-08-12 renamed
	Industry	3D bioprinting
	Industry 2	single cell dispenser
	Person	Forss, Maria (Bico Group 202311– CEO before Vitrolife + AstraZeneca)
	Person 2	Thordenberg, Jacob (Bico 202205 Head of M&A)
	Region	Göteborg (Gothenburg)
	Country	Sweden
	City	n. a.
		Address record changed: 2021-09-23
Basic data	Employees	D: 101 to 500 (2019-08-31)
	Currency	SEK
	Annual sales	105,457,000 (sales, net, consolidated (2018/19) 2019-08-31)
	Profit	581,000 (2019-08-31)
	Cash	198,770,000 (2019-08-31)
		* Document for »About Section«: Bico Group AB. (8/23/21). "Press Release: Dispendix Welcomes Petros Apostolopoulos as New CEO to Strengthen Position as Leading Liquid Handling and Lab Automation Company".
		Record changed: 2023-08-22

Advertisement

More documents for Bico (Group)

• [1] Bico Group AB. (8/21/23). "Press Release: Maria Forss Is Appointed New President and CEO of Bico Group AB (publ)"....
• [2] Bico Group AB. (8/21/23). "Press Release: Bico Announces Goodwill Impairment Predominantly Due to Increased WACC, and Write-downs of Assets"....
• [3] Bico Group AB. (8/3/23). "Press Release: Bico Divests Berlin Property for a Total of EUR 21m"....
• [4] Bico Group AB. (2/27/23). "Press Release: Bico Introduces New Life Sciences Manufacturing Platform Integrating ABB Robotics Technology"....
• [5] Bico Group AB. (1/2/23). "Press Release: Bico Group Appoints New CFO"....
• [6] Sartorius AG. (12/8/22). "Press Release: Sartorius Agrees with Bico on Strategic Cooperation as well as a 10 Percent Capital Investment". Göttingen....
• [7] Scienion AG. (9/13/22). "Press Release: Scienion and Cellenion Launch the proteoCHIP LF 48, for Label-free Single-cell Proteomics Sample Preparation on the cellenONE platform". Berlin & Lyon....
• [8] Scienion GmbH. (7/28/22). "Press Release: Scienion Announces Expansion in the UK with the Opening of New R&D and Manufacturing Facilities". Lakeside North Harbour, Portsmouth....
• [9] Scienion GmbH. (7/5/22). "Press Release: Highfield Diagnostics and Scienion Sign Memorandum of Understanding". Southampton & Berlin....
• [10] Scienion GmbH. (6/1/22). "Press Release: Scienion Appoints Frauke Hein as CEO". Berlin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.